Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension

a vasoactive intestinal peptide and vasoactive technology, applied in the direction of peptide/protein ingredients, extracellular fluid disorder, metabolic disorder, etc., can solve the problem of unsatisfactory pulmonary hypertension treatment, and achieve the effect of prevention and/or treatmen

Inactive Publication Date: 2008-09-11
MONDOBIOTECH AG
View PDF5 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019]It is object of the present invention to provide novel use of known compounds as well as novel compounds, which are useful for the prevention and / or treatment of PPH, SPH, and hypertension of the systemic circulation and methods wherein said compounds are used.

Problems solved by technology

The therapy of pulmonary hypertension is unsatisfactory.
Although the vasodilation in numerous tissues, heart and lung tissue included, there is no clinical evidence up to now that VIP or PACAP are effective in the treatment of pulmonary hypertension in humans.
In particular, endothelial dysfunction leading to decreased bioavailability of nitric oxide impairs endothelium-dependent vasodilation in patients with essential hypertension and may also be a determinant for the premature development of atherosclerosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
  • Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
  • Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0076]A patient with severe PPH was under therapy with diltiazem, furosemid and an anticoagulant. Right heart catheterisation (Swan-Ganz, Baxter, Irvine, Calif., USA) was performed to measure mean pulmonary artery pressure (mpap), cardiac output (CO), mean arterial pressure (MAP), pulmonary capillary wedge pressure (PCWP) mixed venous oxygen saturation (SvO2%) and systemic arterial oxygen pressure (PaO2%). VIP (100 μg in 3 ml NaCl 0.9%) was inhaled for 15 minutes via the MicroDrop Master Jet (MPV, Truma, Germany) using a particle size of 3 μm to provide alveolar deposition of the substance. Alternatively VIP was injected i.v. 20 (ng / kg.b.w. / min) via portable pump system (CADD-1, Pharmacia-Upjohn, Vienna, Austria). Pulmonary homodynamic and gas exchange were measured before and 15 minutes after inhalation or i.v. injection of VIP. Right heart catheterisation was performed in the intensive care unit. The patient was monitored on-line electrocardiographically, invasive blood pressure a...

example 2

[0077]Increased doses of inhaled VIP in a patient suffering from PPH dose-dependently decrease mean pulmonary artery pressure (mPAP) showing maximum efficacy at a dose of 100 μg.

example 3

[0078]100 μg of inhaled PACAP time-dependently decrease mean pulmonary artery pressure (mPAP) in a patient with PPH.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
body weightaaaaaaaaaa
body weightaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

The present invention relates to peptides which are highly biologically and pharmacologically active as therapeutic drug for the treatment of diseases related to hypertension, especially in medical interventions involving dilatation and remodeling of arterial blood vessels, either in the pulmonary or in the systemic circulation. The peptides which can be used according to the invention for the treatment of said diseases comprise at least one specific highly conservative amino acid residue sequence which seem to play an important role in connection with pulmonary and arteriolar hypertension events. It could be shown that the known naturally occurring peptides “vasoactive intestinal peptide (VIP)” and “pituitary adenylate cyclase-activating polypeptide (PACAP)”, having these specific sequences are potent drugs which can be successfully used for treatment of primary pulmonary hypertension (PPH), secondary pulmonary hypertension (SPH), and hypertension of the systemic circulation. Furthermore, the present invention discloses pharmaceutical compositions useful for treatment of PPH, SPH, and hypertension of the systemic circulation within said methods.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation application of U.S. application Ser. No. 10 / 416,822 filed Oct. 3, 2003 which is the national stage entry of PCT application number PCT / EP01 / 13590 filed Nov. 22, 2001, which in turn stems from European Patent Application No. EP 00125935.7, each of which is incorporated by reference in its entirety.[0002]The present invention relates to peptides which are highly biologically and pharmacologically active as therapeutic drug for the treatment of diseases related to hypertension, especially in medical interventions involving dilatation and remodeling of arterial blood vessels, either in the pulmonary or in the systemic circulation. The peptides which can be used according to the invention for the treatment of said diseases comprise at least one specific highly conservative amino acid residue sequence which seem to play an important role in connection with pulmonary and arteriolar hypertension events. It could...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/08A61P9/12A61K38/00A61K38/22A61P9/00A61P9/04A61P11/00C07K7/06C07K7/08C07K14/00C07K14/575
CPCC07K14/57563A61K38/00A61P9/00A61P9/04A61P9/12A61P11/00A61P35/00
Inventor BLOCK, LUTZ-HENNING
Owner MONDOBIOTECH AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap